Trial Profile
A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled, Parallel Efficacy Laboratory Classroom Study With KP415 in Children With Attention-Deficit/Hyperactivity Disorder
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Mar 2023
Price :
$35
*
At a glance
- Drugs Serdexmethylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Registrational; Therapeutic Use
- Acronyms Laboratory Classroom Study
- Sponsors KemPharm; Zevra Therapeutics
- 13 Mar 2023 According to a Corium media release, data from this study will be presented in at the American Neuropsychiatric Association (ANPA) 2023 meeting on Wednesday, March 15, from 5:30 to 7:00 p.m. EDT. in Staffordshire Room of the Westin at Copley Place in Boston, MA.
- 22 Feb 2023 According to a KemPharm media release, KemPharm has changed its name to Zevra Therapeutics.
- 13 Sep 2022 According to a Corium International media release, data from this study will be presented in upcoming Psych Congress 2022; Coriums Psych Congress 2022 posters will be presented on Sunday, September 18, and Monday, September 19, from 1:30 to 3:00 pm CDT (2:30 to 4:00 pm EDT) in Hall D of the New Orleans Convention Center.